Supriya Lifescience's manufacturing unit clears USFDA inspection

April 22, 2026 · 3:16 pm IST Source: Business Standard
๐Ÿ“Œ

Key Takeaways

  • Food and Drug Administration (US FDA) conducted an inspection at the Company's manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026.
  • The inspection concluded with the issuance of a Form 483 containing one (1) minor observation.

Full Report

Supriya Lifescience announced that the U.S. Food and Drug Administration (US FDA) conducted an inspection at the Company's manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026.

The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating Voluntary Action Indicated (VAI), signifying a successful completion of the inspection.

Originally reported by Business Standard.
๐Ÿ’ก

IPO Cracker Take

This market development has implications for IPO investors tracking upcoming issues. See our IPO calendar and live GMP data for the most recent moves.

โ“

Frequently Asked Questions

Market news feeds into IPO pricing decisions, subscription timing, and listing-day sentiment. Track the broader market daily alongside each active IPO's own fundamentals.

Our IPO calendar shows all upcoming, open, and recently listed issues in one place — with price band, GMP, and subscription data.

We publish daily market and IPO news, live GMP updates, and subscription tracking. Bookmark our News page or follow us on social media for real-time updates.
0 Comments

No comments yet. Be the first to share your opinion!